SIGN-UP NOW! SIGN-UP NOW! Click to become a The VoiceAmerica Talk Member for Free!
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 19th 2020: Special Encore "A New Parenteral Treatment for a Severe C. difficile Infection."

Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections

Read more
Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Guest Image

Yannick Pletan, MD Independent Director

Dr Yannick Pletan, Independent Director, Clinical development specialist at Deinove. Doctor of medicine (Paris Descartes University), pulmonologist and immunologist. He holds a Master’s degree in clinical pharmacology and pharmacokinetics, a diploma from the Advanced Leadership program (Harvard Business School) and one in Corporate Finance (HEC).
Read more
Guest Image

Georges Gaudriault, Ph.D. Scientific Director

Georges GAUDRIAULT, PhD, has nearly 20 years of experience in drug research and development. He then masters every step along the value chain, including regulatory aspects and market access. Before joining DEINOVE, he held for nine years the position of Chief scientific officer at MedinCell, a biopharmaceutical company specializing in long-acting drug delivery. He was also a Scientific director at ObeTherapy - a biotechnology start-up specializing in the discovery and development of therapies in the fields of obesity, hypercholesterolemia, and type II diabetes - and contributed to research at the Institut Curie. In addition, Georges GAUDRIAULT has solid experience in the United States, hav
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 05/06/2020 08:00 05/06/2020 09:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections*. DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
Facebook Twitter Linkedin Social Media
presspass-banner